Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 1,857,117 |
|
|||||
| News | - | ||||||
| Day High | 5.145 | Low High |
|||||
| Day Low | 4.885 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Savara Inc | SVRA | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.06 | -1.18% | 5.01 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 5.01 | 4.885 | 5.145 | 5.04 | 5.07 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 9,302 | 1,857,117 | $ 5.02 | $ 9,322,694 | - | 1.69 - 5.70 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 18:18:35 | formt | 500 | $ 5.01 | USD |
Savara Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 697.65M | 138.15M | - | 0 | -54.7M | -0.40 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Savara News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SVRA Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.79 | 5.34 | 4.64 | 5.09 | 825,810 | 0.22 | 4.59% |
| 1 Month | 4.71 | 5.34 | 4.52 | 4.92 | 586,204 | 0.30 | 6.37% |
| 3 Months | 4.43 | 5.70 | 4.41 | 5.00 | 809,757 | 0.58 | 13.09% |
| 6 Months | 3.34 | 5.70 | 3.115 | 4.56 | 776,582 | 1.67 | 50.00% |
| 1 Year | 1.72 | 5.70 | 1.69 | 4.02 | 646,413 | 3.29 | 191.28% |
| 3 Years | 1.73 | 5.70 | 1.02 | 2.74 | 458,449 | 3.28 | 189.60% |
| 5 Years | 9.41 | 11.96 | 0.69 | 2.69 | 684,021 | -4.40 | -46.76% |
Savara Description
| Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). |
